Arteaga CL - Search Results

1

Overcoming Endocrine Resistance in Breast Cancer.

Hanker AB, Sudhan DR, Arteaga CL. Hanker AB, et al. Among authors: arteaga cl. Cancer Cell. 2020 Apr 13;37(4):496-513. doi: 10.1016/j.ccell.2020.03.009. Cancer Cell. 2020. PMID: 32289273 Free PMC article. Review.

2

Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells.

Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK. Arteaga CL, et al. Cancer Res. 1988 Jul 15;48(14):3898-904. Cancer Res. 1988. PMID: 3164252

3

Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.

Arteaga CL, Koli KM, Dugger TC, Clarke R. Arteaga CL, et al. J Natl Cancer Inst. 1999 Jan 6;91(1):46-53. doi: 10.1093/jnci/91.1.46. J Natl Cancer Inst. 1999. PMID: 9890169

4

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.

Arteaga CL. Arteaga CL. Breast Cancer Res. 2003;5(2):96-100. doi: 10.1186/bcr574. Epub 2003 Feb 3. Breast Cancer Res. 2003. PMID: 12631388 Free PMC article.

5

Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?

Arteaga CL, Baselga J. Arteaga CL, et al. Cancer Cell. 2004 Jun;5(6):525-31. doi: 10.1016/j.ccr.2004.05.028. Cancer Cell. 2004. PMID: 15193255 Free article.

6

EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.

Arteaga CL. Arteaga CL. Cancer Cell. 2006 Jun;9(6):421-3. doi: 10.1016/j.ccr.2006.05.014. Cancer Cell. 2006. PMID: 16766261 Free article. Review.

7

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.

Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, Davidson NE. Arteaga CL, et al. Clin Cancer Res. 2008 Oct 1;14(19):6277-83. doi: 10.1158/1078-0432.CCR-08-0482. Clin Cancer Res. 2008. PMID: 18829509 Free PMC article. Clinical Trial.

8

Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.

Rexer BN, Engelman JA, Arteaga CL. Rexer BN, et al. Among authors: arteaga cl. Cell Cycle. 2009 Jan 1;8(1):18-22. doi: 10.4161/cc.8.1.7324. Epub 2009 Jan 30. Cell Cycle. 2009. PMID: 19106609 Free PMC article. Review.

9

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.

Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stål O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL. Miller TW, et al. Among authors: arteaga cl. Cancer Res. 2009 May 15;69(10):4192-201. doi: 10.1158/0008-5472.CAN-09-0042. Epub 2009 May 12. Cancer Res. 2009. PMID: 19435893 Free PMC article.

10

Does lapatinib work against HER2-negative breast cancers?

Mayer IA, Arteaga CL. Mayer IA, et al. Among authors: arteaga cl. Clin Cancer Res. 2010 Mar 1;16(5):1355-7. doi: 10.1158/1078-0432.CCR-09-3223. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179241 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

415 results

Search Page